Depixus awarded a £600k grant from Innovate UK, the UK’s innovation agency

Read More

Depixus UK Ltd, has been awarded a £600k grant by Innovate UK, the UK’s innovation agency, for a project entitled “Complete nucleic acid analysis at genome scale with ultra-high throughput”.   This grant will support the development of one of Depixus’ key technology platforms, which is taking place at the company’s labs in Harston, Cambridgeshire.   Gordon Hamilton, Depixus’ CEO said…

Depixus’ CEO to present at the VIB conference: Revolutionizing Next-Generation Sequencing

Read More

Gordon Hamilton, CEO of Depixus will present the latest results from the company at the Revolutionizing Next-Generation Sequencing meeting, which will be held 25-26 March 2019, in Antwerp, Belgium in a talk entitled “Revealing the living genome: direct decoding of DNA, RNA and modified bases using Depixus’ novel technology.”   From the conference website: After two successful editions (Jan…

Depixus awarded a €2.05m grant through the EU’s H2020 SME Instrument Phase 2 programme

Read More

Depixus announced today that it has been awarded a €2.05m grant through the European Union’s prestigious H2020 SME Instrument Phase 2 programme.   The grant will fund an ambitious project to accelerate commercial development of high-throughput version of Depixus’ instrument system known as MAGNA Digital. This instrument system will be used to reveal important new layers of genetic…

Depixus named laureate in the final of France’s Worldwide Innovation Challenge

Read More

Depixus has been selected as one of only 12 laureates in the final phase of France’s ‘Concours Mondial de l’Innovation’ (Worldwide Innovation Challenge).   This is the culmination of the three rounds of competition, where over 2,000 companies that initially applied were whittled down to 12 laureates. Each of the companies will be eligible to receive up to €20m in financing from a dedicated…

PicoSeq announces corporate name change to Depixus

Read More

PicoSeq announced today that it is changing its corporate name to Depixus. “The name change reflects the company’s breadth of interest across both genetic and epigenetic analysis, with our technology being developed for applications far beyond just DNA sequencing” said Gordon Hamilton, Depixus’ Président (CEO). The new name is effective immediately and will be implemented across the company over…

PicoSeq opens new offices and labs in both France and the UK

Read More

PicoSeq have moved their Paris labs and offices to a new location: 3-5 Impasse Reille in the 14th Arrondissement and have also opened a new R&D base near Cambridge, UK. “These new facilities will allow us to significantly expand our team and the scope of our R&D activities” commented CEO Gordon Hamilton. Contact details for our French and UK R&D sites can be found here.  

PicoSeq chosen for 2nd stage of French world innovation challenge program.

Read More

©présidence de la République/M.ETCHEGOYEN PicoSeq has been selected as one of 16 companies to receive a grant in the second phase of the Concours Mondial de l’Innovation (Worldwide Innovation Challenge). At an award ceremony at the Elysee Palace today, PicoSeq was one of just 3 companies to receive the award in the field of ‘Personalised Medicine’ (one of the 7 categories in the challenge). The…

PicoSeq present poster at the 16th annual AGBT meeting

Read More

PicoSeq was selected to present a poster at the 16th Advances in Genome Technology and Biology (AGBT) meeting held in Marco Island, Florida on the 25-28th of February. Download a copy of the poster here PicoSeq’s CTO Chas André commented, “We continue to develop this exciting new technology, and have been focusing heavily on epigenetics over the past year. We have added a number of new…

Dr. Hamilton to present company update at NGS conference

Read More

Dr. Gordon Hamilton, CEO of PicoSeq will present the latest results from the company at the Revolutionizing Next-Generation Sequencing: Tools and Technologies meeting, which will be held 15-16 January 2015, in Leuven, Belgium. From the conference website: VIB’s Tools and Technologies meeting series aims to provide a forum for both academic top speakers and scientists from emerging companies to…

Dr. Bensimon to present keynote address at NGS conference

Read More

Dr. David Bensimon, Research Director, École Normale Supérieure (and one of the co-founders of PicoSeq) will present the latest results from his lab at the 6th Annual Next Generation Sequencing Congress 2014 to be held the 20th and 21st of November at the Queen Elizabeth II Conference Centre in Westminster, London. Dr. Bensimon will present the a keynote address entitled « Single Molecule…